Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 56,100 shares, a drop of 95.7% from the April 30th total of 1,310,000 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 51,600 shares, the days-to-cover ratio is presently 1.1 days.

Institutional Investors Weigh In On Cardio Diagnostics

Several hedge funds have recently modified their holdings of the company. Two Sigma Securities LLC acquired a new position in shares of Cardio Diagnostics in the fourth quarter valued at approximately $48,000. Jane Street Group LLC bought a new stake in Cardio Diagnostics during the 4th quarter worth approximately $103,000. Millennium Management LLC acquired a new position in Cardio Diagnostics in the 4th quarter valued at approximately $236,000. Finally, Geode Capital Management LLC raised its stake in shares of Cardio Diagnostics by 97.6% during the fourth quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after acquiring an additional 179,978 shares during the last quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Trading Down 2.3%

Cardio Diagnostics stock opened at $4.21 on Friday. Cardio Diagnostics has a 12-month low of $3.40 and a 12-month high of $53.10. The business’s 50-day moving average price is $9.48 and its two-hundred day moving average price is $14.71.

Cardio Diagnostics (NASDAQ:CDIO) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.91). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.05 million. Cardio Diagnostics had a negative net margin of 22,732.03% and a negative return on equity of 258.85%. As a group, equities research analysts forecast that Cardio Diagnostics will post -0.55 EPS for the current year.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.